Latest Market News

Infinity Mining (ASX:IMI) has achieved almost 100% copper extraction from century-old smelter waste at its Cangai site using Orivium’s advanced technology, advancing plans for a new processing plant.

archTIS has locked in a $3.2 million contract with the Australian Department of Defence, renewing Kojensi Enterprise licensing and boosting application development and maintenance services. This deal underpins a key source of recurring revenue and strengthens archTIS’s foothold in Defence’s classified ICT environment.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.

DXN Limited has landed a $1 million contract to deliver a Cable Landing Station in American Samoa, reinforcing its foothold in Pacific telecom infrastructure while divesting a non-core Tasmanian data centre.

Global X Management (AUS) Limited is trimming the management fee for its Australia 300 ETF (ASX: A300) by 25%, effective 1 July 2026, reflecting a subtle but meaningful cost saving for investors.

Enlitic has landed its inaugural Australian Ensight subscription contract with Lumus Imaging, marking a strategic entry into the local SaaS market and expanding its footprint in diagnostic imaging workflows.

Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.

AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.

Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.

Memphasys has locked in a three-year exclusive distribution agreement for its Felix™ sperm separation system in Thailand, targeting a key IVF market with 110 clinics and 20,000–30,000 cycles annually. The deal adds approximately A$430,500 in contracted revenue, lifting South-East Asian minimum contracts to about A$1 million and contributing to FY2026 Felix™ sales now exceeding A$3 million.

The ACCC has rejected Coles’ plan to acquire a leasehold for a new supermarket and liquor store in Kalgoorlie-Boulder, citing risks of reduced competition and the potential exit of an independent rival.